

GLOBAL BIOSIMILAR MARKET

R e p o r t D e s c r i p t i o n

T a b l e o f C o n t e n t s

L i s t o f T a b l e s

S a m p l e T a b l e s

R e l a t e d R e p o r t s

A b o u t M a r k e t s a n d M a r k e t s



MarketsandMarkets Research

108 West 13th Street, Wilmington, DE
19801, County of New Castle

Tel. No.: 1-888-989-8004

Email: sales@marketsandmarkets.com



MARKETSANDMARKETS

Report Description

The increasing demand from patients, insurers, and government agencies to reduce the costs of blockbuster biopharmaceuticals has created numerous opportunities in the global biosimilars market, which is growing at a CAGR of 89.1% from 2009 to 2014 to reach an estimated US\$19.4 billion in 2014.

The biosimilars market is segmented into the submarkets for peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others. Asia's early commercialization and high absorption rate of biosimilars products made it the dominant market in 2008 with 34.1% share of the global biosimilars product market. The American market (including North and Latin America) are expected to account for nearly 35.3% of the total revenues in 2014.


The main factors driving the demand in the biosimilars market include increasing user acceptance, low costs and large application area, increasing governmental initiatives, and the emerging Indian and Chinese economies. The major challenges for the biosimilars market are the risks involved with the high investment and the possible failure of the drugs during development stages. However, opportunities for biosimilars market are immense, as biologics worth



US\$25 billion are going to be off-patent by 2016; and an anticipated approval pathway in U.S. will open up potentially largest market.

Currently, the global biosimilars market is highly fragmented with major players such as Biocon, Dr. Reddy's Lab, Intas, LG LifeSciences, Ranbaxy, Reliance LifeSciences, Sandoz, Teva, and Wockhardt. Favorable regulatory developments in the biosimilars sector are expected to increase the market shares and profit margins while reducing medical expenditure.

Global Biosimilars Market by Products, 2009



In 2009, biosimilars recombinant non glycosylated protein products will form the largest market segment; and are expected to reach US\$11.5 billion by 2014 at a CAGR of 87.9% from the year 2009 to 2014. This is mainly because

most of the branded blockbuster biopharmaceutical drugs such as interferon, human growth hormone-Somatropin, insulin and G-CSF; belong to this class and have wide range of applications.

Report Description

Scope and format

This report aims to identify and analyze biosimilars market on the basis of products, services, technology, and applications.

- **Biosimilars product market**

Peptides, recombinant glycosylated proteins, recombinant non-glycosylated proteins, and others

- **Biosimilars service market**

Contract research and manufacturing services, clinical trials services

- **Biosimilars applications market**

Oncology, infectious diseases, chronic and autoimmune diseases, and other diseases

- **Biosimilars technology market**

Recombinant DNA technology, monoclonal antibodies technologies, protein sequencing, bioassay, chromatography, nuclear magnetic resonance, and mass spectrometry

Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide more than 60 market tables for various geographic regions covering the sub-segments and micro-markets. In addition, the report also provides 40 company profiles for each of its sub-segments.

Table of Contents

1. Introduction

- 1.1 Key take aways
- 1.2 Report description
- 1.3 Markets covered
- 1.4 Stakeholders

2. Summary

- 1.1 Glossary

3. Market overview

- 3.1. Issues Related With Biosimilar
- 3.2 Defining The Global Biosimilar Market
- 3.3 Driving Factor Analysis
 - 3.1. Demand-side Drivers
 - 3.2. Supply-side Drivers
 - 3.3. Restraints & Opportunities
 - 3.4. Key Competitive Points
- 3.4 Potential Matrix For Global Biosimilar Products
- 3.5 Potential Matrix For Global Biosimilar Applications
- 3.6 Biosimilar Market Dynamics
- 3.7 Comparison Of Biosimilar And Generic Drugs
- 3.8 Pricing Of Biosimilar Drug
- 3.9 Supply Side Stakeholders
 - 3.9.1. Innovator Drug Manufacturers
 - 3.9.2. Drug Device Manufacturers & Next-generation Innovators
- 3.10 Biosimilar Products Geographical Trend
- 3.11 Cycle Of Innovation And Competition

4. Biosimilar Products

- 4.1 Summary
- 4.2 Recombinant Non-glycosylated Protein
 - 4.2.1 Drivers
 - 4.2.2 Insulin
 - 4.2.2.1. Drivers & Opportunities
 - 4.2.2.1.1. Increasing Demand From Huge Patient-base
 - 4.2.2.1.2. Improvements In Drug Delivery Method
 - 4.2.3. Recombinant Human Growth Hormone Lepirudin
 - 4.2.4. Interleukin – 2 (IL-2)
 - 4.2.5. Interferons
 - 4.2.5.1. Interferon Alfa
 - 4.2.5.2. Interferon Beta-1a
 - 4.2.5.3. Interferon Gamma
 - 4.2.6. Granulocyte Colony-stimulating Factor (G-CSF)
 - 4.2.7. Interleukin-11
 - 4.2.8. Anakinra
- 4.3 Recombinant Glycosylated Proteins
 - 4.3.1. Drivers & Restraints
 - 4.3.1.1. Applications In Many Therapeutic Indications
 - 4.3.1.2. Segment Covers Major Drug Categories
 - 4.3.1.3. Requires High Degree of Clinical And Manufacturing Expertise
 - 4.3.2. Erythropoietin (EPO)
 - 4.3.3. Follitropin
 - 4.3.4. Thyrotropin
 - 4.3.5. Urokinase
 - 4.3.6. Glucocerebrosidase
 - 4.3.7. Bevacizumab
 - 4.3.8. Granulocyte-macrophage-CSF (GM-CSF)
 - 4.3.9. Recombinant Human Dnase (RHDNASE)
 - 4.3.10. Factor VIIa

Table of Contents

- 4.3.11. Factor VIII
- 4.3.12. Factor IX
- 4.3.13. Activated Protein C
- 4.3.14. Tissue Plasminogen Activator
- 4.3.15. Monoclonal Antibodies
 - 4.3.15.1. Chimaeric Antibodies
 - 4.3.15.2. Humanized / Cdr-grafted / Reshaped Antibodies
 - 4.3.15.3. Human Antibodies And Fusion Protein
- 4.4 Peptides**
 - 4.4.1 Drivers
 - 4.4.1.1. Development Of Synthetic And Biological Peptide Libraries
 - 4.4.1.2. Fewer Side Effects And Maximum Therapeutic Index
 - 4.4.2. Restraints & Opportunities
 - 4.4.2.1. Short Half-life Of Peptide Molecules
 - 4.4.2.2. Costly Manufacturing And Purification Process
 - 4.4.2.3. Approval Of Drug Candidates In Phase II & III
 - 4.4.3. Octreotide
 - 4.4.4. Desmopressin
 - 4.4.5. Cyclosporine
 - 4.4.6. Calcitonin
 - 4.4.7. Eptifibatide
 - 4.4.8. Lh-rh (leuprolide)
 - 4.4.9. Nesiritide
 - 4.4.10. Teriparatide
 - 4.4.11. Bivalirudin
 - 4.4.12. Enfuvirtide
 - 4.4.13. Glucagon

5. Biosimilar Service Market

- 5.1 Summary**
- 5.2 Contract Research And Manufacturing Services**
 - 5.2.1. Drivers
 - 5.2.1.1. Outsourcing Non-core Activities To Low Cost Destinations
 - 5.2.1.2. Time Consuming Nature Of Drug Manufacturing
 - 5.2.2. Restraints & Opportunities
 - 5.2.2.1. Long Inception Period
 - 5.2.2.2. Low Returns
 - 5.2.2.3. Emergence Of Biosimilars

5.3 Clinical Trials

- 5.3.1. Drivers & Restraints
 - 5.3.1.1. Extensive Information About New Drug Candidate
 - 5.3.1.2. Central Role In Drug Development
 - 5.3.1.3. High Cost
- 5.3.2. Phase I
- 5.3.3. Phase II
- 5.3.4. Phase III

6. Biosimilar Application Market

- 6.1 Summary**
- 6.1.1. Drivers
 - 6.1.1.1. Prevalence of Incurable Diseases
 - 6.1.1.2. Expanding Patient Population
 - 6.1.1.3. Developed Technology
 - 6.1.1.4. Increased Life Expectancy
- 6.1.2. Restraints
 - 6.1.2.1. Failure of Clinical Research
 - 6.1.2.2. Adverse Effects of Therapies
- 6.2 Oncology**
 - 6.2.1. Drivers
 - 6.2.1.1. Unraveling of The Genetics Behind Cancer
 - 6.2.1.2. Significance and Variants
 - 6.2.1.3. Availability of New Treatments
 - 6.2.1.4. Increase In The Ageing Population
 - 6.2.2. Restraints & Opportunities
 - 6.2.2.1. Lack of Early Stage Diagnostic
 - 6.2.2.2. Unawareness and Lack of Penetration of Therapeutics

Table of Contents

6.2.3.3. Large Product Pipeline	6.4.6.1. Driver
6.2.4. Lung Cancer	6.4.6.1.1. Risk of Getting Other Diseases
6.2.5. Colorectal Cancer	6.4.6.1.2. Worldwide Prevalence of The Disease
6.2.6. Breast Cancer	6.4.7. Leprosy
6.2.7. Cervical Cancer	6.5 Hematology
6.2.8. Leukemia	6.5.1. Drivers
6.2.8.1. Drivers	6.5.1.1. Prevalence of blood-related disorders
6.2.8.1.1. Huge Market Potential	6.5.1.2. Availability of cheaper treatment alternatives
6.2.8.1.2. Rising Awareness	6.5.1.3. Early start of medication and longer treatment time
6.2.9. Prostate Cancer	6.5.2. Chemotherapy Induced Anemia
6.3 Infectious Diseases	6.5.2.1. Drivers
6.3.1. Hiv/aids	6.5.2.1.1. Chemotherapy has become the preferred treatment
6.3.1.1. Drivers	6.5.2.1.2. Availability of new treatment alternatives
6.3.1.1.1. Continual Research To Increase Market Size	6.5.2.1.3. Early and easy diagnostics drives the market
6.3.1.1.2. Biological Drugs Increase Life Expectancy	6.5.2.2. Restraints and Opportunities
6.3.1.1.3. Less Expensive Than Biological Drugs	6.5.3. Hemophilia
6.3.1.1.4. Lack of Awareness and Access Among Low Income Population	6.5.4. Pulmonary Embolism
6.3.2. Hepatitis B	6.5.4.1. Drivers
6.3.3. Hepatitis C	6.5.4.1.1. Availability of large number of diagnosis tools
6.4 Chronic and Autoimmune Diseases	6.5.4.1.2. Need for immediate medication
6.4.1. Diabetes	6.6 Growth Hormone Deficiency (GHD)
6.4.1.1. Drivers	6.6.1. Drivers
6.4.1.1.1. Awareness & Early Diagnosis Prevents Disease Development	6.6.1.1. Natural deficiency of GH and destruction of normal pituitary gland
6.4.1.1.2. Changing Approach of Patients Towards Medication	6.6.1.2. Need for body mass management
6.4.2. Neutropenia	6.6.1.3. Changes in the body composition
6.4.3. Multiple Sclerosis	6.7 Other Diseases
6.4.3.1. Drivers	6.7.1. Gaucher Disease
6.4.3.1.1. Rising Awareness	6.7.2. Osteoporosis
6.4.3.1.2. Increases The Life Expectancy	6.7.3. Fertility Disorders (Infertility)
6.4.3.2. Inhibitors and Opportunities	6.7.4. Skin Ulcer
6.4.4. Cystic Fibrosis	6.7.5. Hypoglycemia
6.4.5. Rheumatoid Arthritis (RA)	6.7.6. Nocturnal Enuresis
6.4.5.1. Drivers	6.7.7. Congestive Heart Failure (CHF)
6.4.5.1.1. Large Patient Population	6.7.8. Systemic Sepsis
6.4.5.1.2. Need For Continued Treatment	6.7.9. Others
6.4.5.2. Restraints	
6.4.6. Acromegaly	

Table of Contents

7. Biosimilar Technology

7.1. Summary

7.2. Monoclonal Antibodies (MAB) Technology

7.2.1. Drivers

7.2.1.1. Broad Range of Therapeutic, Diagnostic, And Research Applications

7.2.1.2. Low Cost of Development

7.2.1.3. Higher Success Rate

7.2.2. Top Player Analysis

7.3 Recombinant Dna Technology (RDNA Technology)

7.3.1. Drivers

7.3.1.1. Human Therapeutics Application

7.3.1.2. Agricultural Genetic Engineering Application

7.3.1.3. Increase In Demand of Biopharmaceutical Products

7.3.2. Restraints & Opportunities

7.3.2.1. High Cost

7.3.2.2. Risk of Failure

7.3.2.3. Role In Production of Edible Vaccines

7.4 Chromatography

7.4.1. Drivers & Opportunities

7.4.1.1. High resolution refinement

7.4.1.2. Efficacy of end product

7.4.1.3. Wide applications

7.4.1.4. Emergence of biosimilars

7.4.2. Top Player Analysis

7.4.3. Liquid Chromatography (LC)

7.4.4. Gas Chromatography (GC)

7.5 Protein Sequencing

7.5.1. Drivers

7.5.1.1. Applications in life saving drug development

7.5.1.2. Applications in protein classification

7.5.1.3. Use in diagnosis

7.6 Nuclear Magnetic Resonance (NMR) Technology

7.6.1. Drivers

7.6.1.1. Leading technology for 3-D structure

7.6.1.2. Eliminates risk of x-radiation

7.6.1.3. Application in drug delivery system

7.7. Electrophoresis

7.7.1. Drivers

7.7.1.1. Genomic application

7.7.1.2. Most reliable technique

7.7.1.3. Separation Efficacy

7.7.2. Restraints & Opportunities

7.7.2.1. High sample runtime

7.7.3. Gel Electrophoresis

7.7.4. Capillary Electrophoresis

7.8 Mass Spectrometry

7.8.1. Drivers

7.8.1.1. Simple Quantification of Protein Structures

7.8.1.2. Supporting Element for Growing Technologies

7.8.1.3. Gaining Popularity of Hybrid Mass Spectrometry Instruments

7.8.2. Restraints

7.8.2.1. Fails to Analyze Small Quantities of Proteins

7.8.2.2. Manual Interruption Necessary, Increasing the Error Rate

7.9 Western Blotting

7.9.1. Drivers

7.9.1.1. Application in molecular biology disciplines

7.9.1.2. Application in diagnosis of diseases

7.9.1.3. High efficacy at low cost

7.10 Bioassay

7.10.1. Drivers

7.10.1.1. Central role in new drug development

7.10.1.2. Monitoring environmental pollutants

7.10.1.3. Cost benefits and error reduction

7.10.1.4. Shrinking pipelines of new drug candidates

7.10.1.5. Increasing price pressures in the U.S. and Europe

7.10.2. Restraints

7.10.2.1. Accuracy of experiment not guaranteed

7.10.2.2. Time-consuming, laborious, and organism-specific activity

7.10.3. Techniques In Bioassay

7.10.3.1. Six Point Assay

7.10.3.2. Multiple Point Assays

7.10.3.3. Interpolation Method

7.10.3.4. Bracketing Method

7.10.3.5. Matching Bioassays

Table of Contents

8. Geographic Analysis

8.1. American Biosimilar Market

- 8.1.1. Large Patient Base And High Medicare Expenditure
- 8.1.2. Largest Biopharmaceutical Market

8.2 European Biosimilar Market

8.3 Asian Biosimilar Market

8.4 Row Biosimilar Market

9. Regulatory Guidelines

9.1. America

- 9.1.1. Canada
- 9.1.2. U.S.

9.2 Asia

- 9.2.1. Japan

9.2.2. China

9.2.3. India

9.3 Europe

9.4 Row

10. Company profiles

10.1 3sbio (shenyang Sunshine Pharmaceutical Co. Ltd)

10.21 Lg Life Sciences

10.2 Anhui Anke Biotechnology (group) Co., Ltd

10.22 Maxygen

10.3 Bharat Biotech

10.23 Merck

10.4 Bioclones (PTY) Ltd.

10.24 Momenta

10.5 Biocon

10.25 Panacea Biotech

10.6 Biogmerix Ag

10.26 Phage Biotech Corporation

10.7 Biopartners

10.27 Pharmaclon

10.8 Cangene

10.28 Prolong Pharmaceuticals

10.9 Cinnagen Inc.

10.29 Ranbaxy

10.10 Claris Lifesciences

10.30 Reliance Genemedix Plc

10.11 Dong-a Pharmaceutical

10.31 Sandoz (novartis Pharmaceutical)

10.12 Dr. Reddy's Laboratories

10.32 Scigen

10.13 Dsm Biologics

10.33 Scinopharm Taiwan, Ltd.

10.14 Dynavax Technologies

10.34 Shantha Biotech

10.15 Emcure

10.35 Shenzhen Neptunus Interlong

10.16 Genescience Pharmaceuticals Co Ltd.

10.36 Shreya Life Sciences Ltd.

10.17 Glenmark Pharmaceuticals

10.37 Stada Arzneimittel Ag

10.18 Gtc Biotherapeutics Ltd.

10.38 Teva Pharmaceutical Industries Ltd.

10.19 Hospira Inc.

10.39 Vipro International Inc.

10.20 Intas Biopharmaceuticals Ltd.

10.40 Wockhardt Limited

Table of Contents

11. Patent Analysis

- 11.1 Patent Expiration In 2008 And Before
 - 11.2 Patent Expiration In 2009 And After
-

12. Appendix

12.1 Patent Expiry In 2008 And Before

- 12.1.1. U.S. Biopharmaceutical Patents
- 12.1.2. European Biopharmaceutical Patents
- 12.1.3. Asian Biopharmaceutical Patents

12.2 Patent Expiry In 2009 And After

- 12.2.1. U.S. Biopharmaceutical Patents
 - 12.2.2. European Biopharmaceutical Patents
 - 12.2.3. Asian Biopharmaceutical Patents
-

List of Tables

- Summary Global Biosimilar Market, by Products 2007 – 2014 (\$ Thousands) 2007 – 2014 (\$ Thousands)
- 1 Global Biosimilar Non-glycosylated Protein Market, by Product 2007 – 2014 (\$ Thousands)
 - 2 Global Biosimilar Recombinant Non-glycosylated Protein Market, by Geography 2007 – 2014 (\$ Thousands)
 - 3 Major Players And Their Respective Developments
 - 4 Global Biosimilar Recombinant Insulin Market, by Geography 2007 – 2014 (\$ Thousands)
 - 5 Global Biosimilar Rhg Market, by Geography 2007 – 2014 (\$ Thousands)
 - 6 Global Biosimilar Lepirudin Market, by Geography 2007 – 2014 (\$ Thousands)
 - 7 Global Biosimilar Recombinant Interleukin-2 Market, by Geography 2007 – 2014 (\$ Thousands)
 - 8 Global Biosimilar Recombinant Interferons Market, by Product 2007 – 2014 (\$ Thousands)
 - 9 Global Biosimilar Recombinant Interferons Market, by Geography 2007 – 2014 (\$ Thousands)
 - 10 Global Biosimilar Recombinant Interferon Alfa Market by Geography 2007 – 2014 (\$ Thousands)
 - 11 Global Biosimilar Recombinant Interferon Beta-1a Market, by Geography 2007 – 2014 (\$ Thousands)
 - 12 Global Biosimilar Recombinant Interferon Gamma Market, by Geography 2007 – 2014 (\$ Thousands)
 - 13 Global Biosimilar Recombinant Granulocyte Colony-stimulating Factor (g-csf) Market, by Geography 2007 – 2014 (\$ Thousands)
 - 14 Global Biosimilar Recombinant Interleukin-11 Market, by Geography 2007 – 2014 (\$ Thousands)
 - 15 Global Biosimilar Recombinant Anakinra Market, by Geography 2007 – 2014 (\$ Thousands)
 - 16 Global Biosimilar Glycosylated Protein Market, by Products 2007 – 2014 (\$ Thousands)
 - 17 Global Biosimilar Glycosylated Protein Market, by Geography 2007 – 2014 (\$ Thousands)
 - 18 Major Players And Their Respective Developments
 - 19 Global Biosimilar Recombinant Epo Market, by Geography 2007 – 2014 (\$ Thousands)
 - 20 Global Biosimilar Follitropin Market, by Geography 2007 – 2014 (\$ Thousands)
 - 21 Global Biosimilar Thyrotropin Market, by Geography 2007 – 2014 (\$ Thousands)60
 - 22 Global Biosimilar Urokinase Market, by Geography 2007 – 2014 (\$ Thousands)
 - 23 Global Biosimilar Glucocerebrosidase Market, by Geography 2007 – 2014 (\$ Thousands)
 - 24 Global Biosimilar Bepaclermin Market, by Geography 2007 – 2014 (\$ Thousands)
 - 25 Global Biosimilar Recombinant Gm-csf Market, by Geography 2007 – 2014 (\$ Thousands)
 - 26 Global Biosimilar Rhdnase Market, by Geography 2007 – 2014 (\$ Thousands)
 - 27 Global Biosimilar Factor Viia Market, by Geography 2007 – 2014 (\$ Thousands)
 - 28 Global Biosimilar Factor Viii Market, by Geography 2007 – 2014 (\$ Thousands)
 - 29 Global Biosimilar Factor Ix Market, by Geography 2007 – 2014 (\$ Thousands)
 - 30 Global Biosimilar Activated Protein C Market, by Geography 2007 – 2014 (\$ Thousands)
 - 31 Global Biosimilar Tpa Market, by Geography 2007 – 2014 (\$ Thousands)
 - 32 Global Biosimilar Monoclonal Antibodies Market, by Geography 2007 – 2014 (\$ Thousands)
 - 33 Global Biosimilar Peptide Market, by Products 2007 – 2014 (\$ Thousands)
 - 34 Global Biosimilar Peptide Market, by Geography 2007 – 2014 (\$ Thousands)
 - 35 Major Players And Their Respective Developments
 - 36 Global Biosimilar Octreotide Peptide Market, by Geography 2007 – 2014 (\$ Thousands)
 - 37 Global Biosimilar Desmopressin Peptide Market, by Geography 2007 – 2014 (\$ Thousands)
 - 38 Global Biosimilar Cyclosporine Peptide Market, by Geography 2007 – 2014 (\$ Thousands)
 - 39 Global Biosimilar Calcitonin Peptide Market, by Geography 2007 – 2014 (\$ Thousands)
 - 40 Global Biosimilar Eptifibatide Peptide Market, by Geography 2007 – 2014 (\$ Thousands)
 - 41 Global Biosimilar Lh-rh Peptide Market, by Geography 2007 – 2014 (\$ Thousands)
 - 42 Global Biosimilar Nesiritide Peptide Market, by Geography 2007 – 2014 (\$ Thousands)
 - 43 Global Biosimilar Teriparatide Peptide Market, by Geography 2007 – 2014 (\$ Thousands)
 - 44 Global Biosimilar Bivalirudin Peptide Market, by Geography 2007 – 2014 (\$ Thousands)
 - 45 Global Biosimilar Enfuvirtide Peptide Market, by Geography 2007 – 2014 (\$ Thousands)
 - 46 Global Biosimilar Glucagon Peptide Market, by Geography 2007 – 2014 (\$ Thousands)
 - 47 Major Players And Developments
 - 48 Global Biosimilar Market, by Applications 2007 – 2014 (\$ Thousands)
 - 49 Global Biosimilar Oncology Market, by Types

List of Tables

- 2007 – 2014 (\$ Thousands)
- 50 Global Biosimilar Infectious Diseases Market, by Types 2007 – 2014 (\$ Thousands)
- 51 Global Biosimilar Chronic And Autoimmune Disease Market, by Types 2007 – 2014 (\$ Thousands)
- 52 Global Biosimilar Hematology Market, by Types 2007 – 2014 (\$ Thousands)
- 53 Global Biosimilar Other Diseases Market, by Types 2007 – 2014 (\$ Thousands)
- 54 Major Players and Developments
- 55 Major Players and Developments
- 56 Global Biosimilar Market, by Geography 2007 – 2014 (\$ Thousands)
- 57 American Biosimilar Market, by Segments 2007 – 2014 (\$ Thousands)
- 58 European Biosimilar Market, by Segments 2007 – 2014 (\$ Thousands)
- 59 Asian Biosimilar Market, by Segments 2007 – 2014 (\$ Thousands)
- 60 Row Biosimilar Market, by Segments 2007 – 2014 (\$ Thousands)

List of Figures

- 1 Market Transition Impacting Biosimilar Market
- 2 Issues Related With Biosimilar
- 3 Biosimilar Market Definition
- 4 Driving Factor Analysis of Global Biosimilar Market
- 5 Market Potential Matrix for Global Biosimilar Product Market, 2009
- 6 Market Potential Matrix for Global Biosimilar Application Market, 2009
- 7 Global Biosimilar Market Dynamics
- 8 Comparison of Biosimilar And Generic Drugs
- 9 Pricing of Biosimilar Drug
- 10 Supply Side Stakeholders
- 11 Biosimilar Products Geographical Trend
- 12 Cycle Of Innovation and Competition
- 13 Biosimilar Product Market Trend
- 14 European Biosimilar Market Dynamics
- 15 Global Biopharmaceutical Patents, by Segment
- 16 Global Biopharmaceutical Patents, by Geography
- 17 U.S. Biopharmaceutical Patents, by Segment
- 18 Europe Biopharmaceutical Patents, by Segment
- 19 Asia Biopharmaceutical Patents, by Segment
- 20 Global Biopharmaceutical Patents, by Segment
- 21 Global Biopharmaceutical Patents, by Geography
- 22 U.S. Biopharmaceutical Patents, by Segment
- 23 Europe Biopharmaceutical Patents, by Segment
- 24 Asia Biopharmaceutical Patents, by Segment

Sample Tables

Global biosimilar market by product					
	2007	2008	2009	2014	CAGR 2009-2014
Recombinant Non-glycosylated protein					
Recombinant glycosylated protein					
Peptides					
Others					
Total					

Global biosimilar market by Region					
	2007	2008	2009	2014	CAGR 2009-2014
America					
Europe					
Asia					
ROW					
Total					

Global biosimilar non-glycosylated protein market by Product					
	2007	2008	2009	2014	CAGR 2009-2014
Interferons					
Human Growth Hormone (Somatropin)					
Granulocyte-CSF					
Insulin					
Interleukin-2					
Lepirudin					
Interleukin-11					
Anakinra					
Total					

Sample Tables

Global biosimilar recombinant non-glycosylated protein market by Region					
	2007	2008	2009	2014	CAGR 2009-2014
America					
Europe					
Asia					
Row					
Total					

Global biosimilar recombinant insulin market by Geography					
	2007	2008	2009	2014	CAGR 2009-2014
America					
Europe					
Asia					
Row					
Total					

Global biosimilar peptide market by Product					
	2007	2008	2009	2014	CAGR 2009-2014
LH-RH					
Glucagon					
Cyclosporine					
Calcitonin					
Desmopressin					
Octreotide					
Eptifibatide					
Bivalirudin					
Teriparatide					
Enfuvirtide					
Nesiritide					
Total					

Sample Tables

Global biosimilar rhGH market by Geography					
	2007	2008	2009	2014	CAGR 2009-2014
America					
Europe					
Asia.					
ROW					
Total					

Global biosimilar recombinant interleukin market by Geography					
	2007	2008	2009	2014	CAGR 2009-2014
America					
Europe					
Asia.					
ROW					
Total					

Global biosimilar recombinant interferons market by Product					
	2007	2008	2009	2014	CAGR 2009-2014
Interferon- Alfa					
Interferon- Beta-1a					
Interferon- Gamma					
Total					

Sample Tables

Global biosimilar glycosylated protein market by Product					
	2007	2008	2009	2014	CAGR 2009-2014
Erythropoietin					
Granulocyte-macrophage-CSF					
Monoclonal Antibodies					
Glucocerebrosidase					
Follitropin					
Urokinase					
Factor VIII					
Factor IX					
Factor VIIa					
Tissue plasminogen activator					
Human Activated protein C concentrate					
DNase					
Thyrotropin					
Becaplermin					
Total					

Sample Tables

Sample Tables

Global biosimilar market by Application					
	2007	2008	2009	2014	CAGR 2009-2014
Hematology					
Chronic and Autoimmune					
disease					
Growth Related Deficiencies					
Oncology					
Infectious Diseases					
Other Diseases					
Total					

Global biosimilar oncology market by Type					
	2007	2008	2009	2014	CAGR 2009-2014
Leukemia					
Prostate cancer					
Breast cancer					
Lung cancer					
Colorectal cancer					
Cervical cancer					
Others					
Total					

Global biosimilar infectious diseases market by Type					
	2007	2008	2009	2014	CAGR 2009-2014
Hepatitis B (HBV)					
Hepatitis C (HCV)					
HIV/AIDS					
Total					

Key Questions

The Report Answers The Following Questions:

- Which are the high growth segments/cash cows?
- How is the market segmented in terms of applications, products, and ingredients?
- What are market estimates and forecast?
- Which markets are doing well and which are not?
- Where are the gaps and opportunities?
- Which are the key playing fields?
- How is the competitive outlook?
- Who are the main players in each of the segments?

Disclaimer

MarketsandMarkets strategic analysis services are limited publications containing valuable market information provided to a select group of customers in response to orders. Our customers acknowledge when ordering that MarketsandMarkets strategic analysis services are for our customers' internal use and not for general publication or disclosure to third parties.

Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation.

MarketsandMarkets takes no responsibility for any incorrect information supplied to us by manufacturers or users.

No part of this strategic analysis service may be given, lent, resold or disclosed to non-customers without written permission.

Furthermore, no part may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without the permission of the publisher.

For information regarding permission, contact:

Tel: 1-888-989-8004

Email: sales@marketsandmarkets.com

Copyright©2010 MarketsandMarkets

All Rights Reserved. This document contains highly confidential information and is the sole property of MarketsandMarkets. No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of MarketsandMarkets.

About MarketsandMarkets

We publish about 120 reports a year across 10 main industries. The reports are exhaustive, detailing about 50 micro markets and product segments, and featuring about 80 to 100 market data summary tables, 50 short company profiles, a five-level market breakdown, overviews of more than 300 patents, as well as analyses of the strategic and competitive landscape.

Our clients value our reports especially for the market insight we provide along with the market numbers. Our teams of specialized market analysts and domain experts work within a structured research process to deliver well-analyzed market reports to Fortune 1000 companies globally.

[Click here to learn more about us](#)

[Click here to visit our website](#)

Related Reports

Global Biomaterial Market (2009-2014)

For the past 100 years, biomaterials have been used in the human body to improve the body functions and replace the damaged tissues of the body. These materials have been evolved from inert biomaterials to biodegradable biomaterials that can be dissolved in the body. Advances in technology and emergence of innovative products have enhanced the performance and applications of these biomaterials.

Report code: BT1026

Price: \$4650

Global Injectable Drug Delivery Market

In addition to the market size, data trends and forecasts, the report will also highlight key opportunity areas for the relevant stakeholders. We will analyze new product launches. In addition, we will analyze and profile key market developments of the top companies in this market and its sub-segments while drawing a competitive landscape for major markets and their sub segments.

Report code: BT 1113

Price: \$4650

Biomarkers- Advanced Technologies and Global Market (2009-2014)

The application of biomarkers is expected to change the approach in which pharmaceutical companies evaluate the economic feasibility of the drug discovery process. Biomarkers are being increasingly used for the discovery of promising and effective drugs; and this has significantly improved the understanding of the development process. The commercially emergence of biomarkers in the field of molecular diagnostics boosts their shift towards the area of personalized medicine

Report code: BT1033

Price: \$4650